US 12,168,004 B2
Treatment of migraine
Mary Ann Johnson, Norristown, PA (US); Leonardo Resende Allain, Lansdale, PA (US); W. Mark Eickhoff, Lansdale, PA (US); Craig B. Ikeda, Harleysville, PA (US); Chad D. Brown, Quakertown, PA (US); Francis J. Flanagan, Jr., North Wales, PA (US); Rebecca Nofsinger, Lansdale, PA (US); Melanie J. Marota, Mount Laurel, NJ (US); Lisa Lupton, South San Francisco, CA (US); Paresh B. Patel, Langhome, PA (US); Hanmi Xi, Furlong, PA (US); and Wei Xu, North Wales, PA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed by Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed on May 13, 2024, as Appl. No. 18/663,025.
Application 18/663,025 is a division of application No. 18/440,217, filed on Feb. 13, 2024.
Application 18/440,217 is a continuation in part of application No. 18/523,481, filed on Nov. 29, 2023.
Application 18/523,481 is a continuation of application No. 18/210,719, filed on Jun. 16, 2023, granted, now 11,857,542, issued on Jan. 2, 2024.
Application 18/210,719 is a continuation of application No. 17/559,177, filed on Dec. 22, 2021, granted, now 11,717,515, issued on Aug. 8, 2023.
Application 18/440,217 is a continuation in part of application No. 18/137,925, filed on Apr. 21, 2023.
Application 18/137,925 is a continuation of application No. 17/110,398, filed on Dec. 3, 2020, granted, now 11,925,709, issued on Mar. 12, 2024.
Application 17/110,398 is a continuation of application No. 16/178,641, filed on Nov. 2, 2018, abandoned.
Application 16/178,641 is a continuation of application No. 15/115,026, granted, now 10,117,836, issued on Nov. 6, 2018, previously published as PCT/US2015/013672, filed on Jan. 30, 2015.
Claims priority of provisional application 63/129,379, filed on Dec. 22, 2020.
Claims priority of provisional application 61/936,019, filed on Feb. 5, 2014.
Claims priority of provisional application 62/087,366, filed on Dec. 4, 2014.
Prior Publication US 2024/0299369 A1, Sep. 12, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4375 (2006.01); A61K 31/4545 (2006.01); A61P 25/06 (2006.01)
CPC A61K 31/4375 (2013.01) [A61K 31/4545 (2013.01); A61P 25/06 (2018.01)] 30 Claims
 
1. A rapidly-disintegrating pharmaceutical tablet comprising:
(a) an extrudate comprising:
(i) a polymer matrix,
(ii) a compound of Formula Ia,

OG Complex Work Unit Chemistry
wherein each of Rb is —H, and
(iii) a dispersing agent,
wherein the compound of Formula Ia is dispersed within the polymer matrix, and
(b) a disintegration system;
wherein said tablet achieves complete disintegration in less than about 5 minutes in a tablet disintegration test complying with USP 31-NF26 Chapt. 701 using aqueous HCl at pH 1.8 at 37° C.